Condition: Acute Myeloid Leukemia · Myelodysplastic Syndrome · Sponsor: Remedy Plan, Inc.
The main goals of this study are to learn if RPT1G is safe and tolerable and to determine the best dose and schedule of RPT1G for patients with relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).
This description comes directly from the study's public registry record.
Eunice Vukosavljevic, CP, Director of Clinical Operations · 240-408-4854 · clinical@remedyplan.com
Always discuss trial participation with your own doctor first.
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Recruiting |
| MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07107126